Monday, July 2, 2012

New Migraine Guidelines Include Non-prescription Alternatives


From a report by Stephen D. Silberstein, MD

Neurologists and other physicians who care for patients with migraine must be prepared to offer appropriate preventive treatments… clinicians should be ready to offer therapies with the greatest potential to reduce the frequency, severity, or duration of migraines for that particular patient. The focus on non-prescription and non-traditional interventions for migraine is especially important. Although some clinicians are dismissive of complementary therapies, the comprehensive literature review undertaken for the guideline development shows that controlled trials have been conducted for some therapies. Furthermore, some of these trials show that these non-prescription agents may offer promise in the management of migraine. Those individuals interested in treatment alternatives can be directed to agents with evidence.

Full report at http://bmctoday.net/practicalneurology/2012/06/article.asp?f=new-guidelines-update-approach-to-episodic-migraine-prevention

Stephen D. Silberstein, MD is Professor of Neurology and Director of the Jefferson Headache Center at Thomas Jefferson University. He is a Fellow of the American College of Physicians (ACP) and the American Headache Society (AHS), and the American Academy of Neurology (AAN).

Today many doctors and clinicians include Tuliv Migraine Defense as part of the recommended migraine treatment plan for patients. For more information on Tuliv Migraine Defense and why physicians recommend it, see http://Tuilv.com